You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

344 Results
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    luspatercept - For the treatment of red-blood cell (RBC) transfusion-dependent anemia associated with Myelodysplastic Syndromes (MDS), according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
luspatercept
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Document
Apr 2021
Regimen
Cancer Type:
Lung, 
Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
lurbinectedin (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Endocrine, 
Adrenal, 
Neuroendocrine, 
Pancreatic Neuroendocrine, 
Parathyroid, 
Thymoma, 
Thyroid, 
Gastrointestinal, 
Anus, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Gastrointestinal Stromal Tumours, 
Hepatobiliary / Liver / Bile Duct, 
Mesothelioma (Peritoneal), 
Neuroendocrine (GI), 
Pancreas, 
Rectal, 
Small bowel and appendix, 
Genitourinary, 
Bladder / Urothelial, 
Penile, 
Prostate, 
Renal cell / Kidney, 
Testis, 
Gynecologic, 
Cervix, 
Endometrial, 
Germ Cell, 
Gestational Trophoblastic Disease, 
Ovary, 
Uterine Sarcoma, 
Vagina, 
Vulva, 
Head and Neck, 
Larynx, 
Nasopharynx, 
Oral, 
Paranasal Sinus, 
Pharynx, 
Salivary Gland, 
Squamous Cell, 
Kaposi's Sarcoma, 
Lung, 
Mesothelioma (Pleural), 
Neuroendocrine (Lung), 
Non-Small Cell, 
Small Cell, 
Sarcoma, 
Desmoid Tumour, 
Ewing's, 
Ewing's and Soft Tissue, 
GIST, 
Giant Cell Tumour, 
Kaposi's Sarcoma, 
Osteogenic / Bone, 
Soft Tissue, 
Uterine, 
Wilm's Tumour, 
Skin, 
Basal Cell, 
Melanoma, 
Merkel Cell, 
Squamous Cell, 
Unknown Primary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
larotrectinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Document
Nov 2021
Guidelines and Advice
May 2021
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - In Combination with Pembrolizumab for Advanced Endometrial Cancer
New Drug Funding Program
    Pembrolizumab - In Combination with Lenvatinib for Advanced Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lenvatinib,
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023

Pages